Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2775 EUR 3.16% Market Closed
Market Cap: 32.1m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.3876 EUR with a low forecast of 0.3636 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.3636 EUR
31% Upside
Average
Price Target
0.3876 EUR
40% Upside
Highest
Price Target
0.42 EUR
51% Upside
Gensight Biologics SA Competitors:
Price Targets
ACLX
Arcellx Inc
57% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
28% Upside
206650
EuBiologics Co Ltd
37% Upside
NVAX
Novavax Inc
104% Upside
SGMO
Sangamo Therapeutics Inc
156% Upside
DVYSR
Devyser Diagnostics AB
28% Upside
688428
InnoCare Pharma Ltd
34% Upside
HPHA
Heidelberg Pharma AG
408% Upside

Revenue
Forecast

Revenue Estimate
Gensight Biologics SA

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 32%.

N/A
Past Growth
32%
Estimated Growth
Estimates Accuracy
-54%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.3876 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.3876 EUR with a low forecast of 0.3636 EUR and a high forecast of 0.42 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
32%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 32%.

Back to Top